Hematopoietic Stem Cell Transplantation for Children with Malignant Lymphoma in Korea: Multicenter Retrospective Study.
- Author:
Bo Hyun KIM
1
;
Sung Chul WON
;
Hee Young SHIN
;
Hyo Seop AHN
;
Tai Ju HWANG
;
Hoon KOOK
;
Hong Hoe KOO
;
Ki Woong SUNG
;
Keon Hee YOO
;
Hack Ki KIM
;
Bin CHO
;
Nak Gyun CHUNG
;
Joon Eun PARK
;
Jeong Ok HAH
;
Thad T GHIM
;
Hyung Nam MOON
;
Jong Jin SEO
;
Jae Sun PARK
;
Young Ho LEE
;
Eun Sun YOO
;
Chuhl Joo LYU
Author Information
1. Department of Pediatrics, College of Medicine, Yonsei University, Seoul, Korea. cj@yumc.yonsei.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Non Hodgkin's lymphoma;
Hodgkin's disease;
Stem cell transplantation
- MeSH:
Child;
Diagnosis;
Drug Therapy;
Follow-Up Studies;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Hodgkin Disease;
Hospitals, Teaching;
Humans;
Korea*;
Lymphoma*;
Lymphoma, Non-Hodgkin;
Mortality;
Prognosis;
Surveys and Questionnaires;
Recurrence;
Retrospective Studies*;
Stem Cell Transplantation;
Survival Rate
- From:Korean Journal of Pediatric Hematology-Oncology
2005;12(1):18-27
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Children with Malignant lymphoma who is in the advanced stage at diagnosis or relapses during treatment have a poor prognosis. Recently, hematopoietic stem cell transplantation (HSCT) for advanced stage or refractory/relapsed lymphoma performed frequently. However, the role for HSCT for children with malignant lymphoma is still controversial. In this study, we reviewed children with malignant lymphoma who received HSCT and analyzed the results. METHODS: Questionnaires were made and sent to a group of teaching hospitals, with a return of 37 questionnaires from 11 hospitals. 33 patients with Non-Hodgkin lymphoma (NHL) and 4 patients with Hodgkin disease (HD) who received HSCT from 1997 to 2004 in Korea were enrolled in this study. Disease state at diagnosis, relapses during treatment, disease state at HSCT, and survival record were analyzed. All Data were reviewed with the questionnaires from the 11 teaching hospitals. RESULTS: Four patients with HD received HSCT at the 2nd complete remission after relapse. Survival rate for HD was 100% and their follow up duration ranged from 0.2 to 6.2 years (median 2.4 years). The 2-year survival rate for NHL was 68.1+/-9.0% and their follow up duration ranged from 0.1 to 7.6 years (median 1.5 years). The 2-year survival rate in patients with advanced stage at diagnosis and in relapsed/refractory patients were 83.6+/-1.1% and 55.9+/-12.9%, respectively (P=0.12). The mortality asssociated with HSCT was only 1 case, and most of the transplantation related complications did not resulted in death. CONCLUSION: Our results suggest that high dose chemotherapy followed by HSCT in children with malignant lymphoma is a safe procedure, which at the same time improves the results of standard treatment.
